Nuvation Bio (NUVB) Interest & Investment Income (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Interest & Investment Income of $5.1 million for Q1 2026, down 4.0% year-over-year from $5.3 million in Q1 2025, and down 3.55% quarter-over-quarter from $5.3 million in Q4 2025.
Nuvation Bio (NUVB) Interest & Investment Income (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Interest & Investment Income for 7 consecutive years, with $5.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income fell 4.0% year-over-year to $5.1 million; the TTM figure through Mar 2026 stood at $21.2 million (down 15.98% YoY), while the FY2025 annual figure was $21.4 million, down 20.81% from the prior year.
- Interest & Investment Income declined to $5.1 million in Q1 2026 per NUVB's latest filing, from $5.3 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $7.1 million in Q2 2024 and bottomed at $841000.0 in Q2 2022.
- Historically, Interest & Investment Income has averaged $5.0 million across 5 years, with a median of $5.3 million in 2025.
- Annual changes were most pronounced in 2023 — Interest & Investment Income surged 623.66% — and 2025, when it plunged 33.09%.
- Nuvation Bio's Interest & Investment Income stood at $3.5 million in 2022, then soared by 99.35% to $7.0 million in 2023, then fell by 13.68% to $6.1 million in 2024, then slipped by 12.64% to $5.3 million in 2025, then fell by 3.55% to $5.1 million in 2026.
- Business Quant data shows NUVB's Interest & Investment Income at $5.1 million in Q1 2026, $5.3 million in Q4 2025, and $6.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | 4.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.60 Mn |
| Mar 31, 2026 | 5.11 Mn |
| Dec 31, 2025 | 5.30 Mn |
| Sep 30, 2025 | 6.03 Mn |
| Jun 30, 2025 | 4.78 Mn |
| Mar 31, 2025 | 5.32 Mn |
| Dec 31, 2024 | 6.06 Mn |
| Sep 30, 2024 | 6.73 Mn |
| Jun 30, 2024 | 7.14 Mn |
| Mar 31, 2024 | 7.13 Mn |
| Dec 31, 2023 | 7.02 Mn |
| Sep 30, 2023 | 6.52 Mn |
| Jun 30, 2023 | 6.09 Mn |
| Mar 31, 2023 | 4.98 Mn |
| Dec 31, 2022 | 3.52 Mn |
| Sep 30, 2022 | 2.13 Mn |
| Jun 30, 2022 | 841,000.00 |
| Mar 31, 2022 | 958,000.00 |
| Dec 31, 2021 | 902,000.00 |
| Sep 30, 2021 | 847,000.00 |